Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume: 1

Indexed in: EBSCO.

Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for ...
[view complete introduction]


Back


The Current Status of Cladribine in the Treatment of Lymphoid and Myeloid Malignancies

Pp. 69-114 (46)

Tadeusz Robak and Pawel Robak

Abstract

Cladribine (2-CdA, 2-chlorodeoxyadenosine) is a purine nucleoside analog of high efficacy in lymphoid and myeloid malignancies. In contrast to other purine nucleoside analogs, 2-CdA is equally cytotoxic to both proliferating and quiescent cells. In addition, recent data indicates that a combination of 2-CdA with other cytotoxic agents and monoclonal antibodies shows synergistic proapoptotic and cytotoxic activity on lymphoid and myeloid neoplastic cells. Cladribine is the drug of choice in the treatment of hairy cell leukemia. It is also useful in other lymphoid and myeloid neoplasms, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and non-Hodgkin lymphoma. In addition, 2-CdA has been found to be effective in Sezary syndrome and mycosis fungoides. Moreover, several investigations have revealed that the agent is active in acute myeloid leukemia, Langerhans cell histiocytosis, and systemic mastocytosis. This chapter will summarize the current status of 2-CdA in the treatment of hematologic malignancies.

Keywords:

2-CdA, Acute myeloid leukemia, Chronic lymphocytic leukemia, Cladribine, Hairy cell leukemia, Langerhans cell histiocytosis, Lymphoma, Systemic mastocytosis, Waldenström macroglo-bulinemia.

Affiliation:

Department of Hematology, Medical University of Lodz, 93-510 Łódź, Ciolkowskiego 2, Poland.